We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Welcome back to our continued deep dive into packaging components. In Part 1, we explored key regulatory frameworks that shape packaging components in pharmaceuticals, such as USP <382> (effective from 01 Dec 2025), EU GMP Annex 1, and EU Medical Device Regulation (MDR) 2017/745. These guidelines underscore the importance of ensuring packaging components maintain drug integrity and safety, focusing on aspects like functional suitability, aseptic processing, and comprehensive compliance documentation.
We discussed the critical nature of compatibility between drug formulations and packaging materials, highlighting how both chemical and physical interactions affect drug stability, potency, and safety. This evaluation is vital for protecting product efficacy and patient well-being.
Additionally, we examined the significance of protection from extractables and leachables through advanced testing and use of FluroTec™ barrier film on components, which enhance material compatibility and reduces extractables and leachables risk.
Lastly, we delved into the design of packaging components, emphasizing the importance of design for manufacturability (DFM) and Quality by Design (QbD) principles to ensure high-quality, efficient, and reliable drug delivery. NovaPure® stoppers combine the protection of FluroTec™ barrier film, West Envision™ verification process and lot-to-lot extractables testing with the assurance that comes from deep process understanding and manufacturing controls based on Quality by Design (QbD) principles rep resent the pinnacle of packaging solutions that meet the demanding standards of high-value biologics and small molecules.
We will now explore crucial considerations including container closure integrity testing, preparation methods and specifications, sterilization processes, and extensive documentation and services.
Container closure integrity (CCI) is crucial for testing maintaining the sterility and quality of injectable drug products. The evaluation begins with theoretical assessments through interference fit analysis and stack-up analysis to ensure the correct combination of packaging components for effective CCI. Following this, modeling approaches such as Finite Element Analysis (FEA) are employed, where complex shapes are divided into finite elements for structural analysis. Another approach, using Computed Tomography (CT) scanning; employing X-rays to visualize the internal structure of assembled objects in three dimensions.
Subsequently, CCI testing should be conducted using the quantitative test methods recommended in USP <1207 >. It is crucial to select a suitable CCI method that is sensitive enough to detect a leak at an application's maximum allowable leakage limit (MALL). Before proceeding with product testing, these testing methods must undergo a thorough validation process to ensure their accuracy and reliability in detecting the specified leakage limits. This validation is essential to confirm that the chosen method(s) is/are capable of meeting the stringent requirements for maintaining CCI across all applicable scenarios.
The preparation methods and specifications of packaging components must meet stringent industry standards to ensure quality and performance. This involves selecting high-purity materials and applying well-controlled manufacturing processes. Packaging components, especially elastomeric ones, undergo rigorous washing and sterilization processes to ensure they are free from contaminants.
The Westar®, Westar® Select and NovaPure® components a re integral to West’s approach to providing high-quality packaging components for the pharmaceutical industry. These processes are designed to ensure that elastomeric components meet stringent specifications for bioburden, endotoxin levels, and particulate matter, thereby supporting the integrity and safety of drug products.
The Westar® and Westar® Select component manufacturing processes involve a validated washing cycle that significantly reduces bacterial endotoxin content by at least 99.9% (3 .0-log reduction), as well as particulate matter and bioburden to meet established specification limits. These processes are performed in a controlled environment, typically in Zone 5 clean room, ensuring that the components are free from contaminants before they are shipped to customers for sterilization. The Westar® and Westar® Select component manufacturing processes are globally standardized, allowing for consistent preparation of elastomeric components from clinical phases through to marketed products. This standardization helps mitigate risks associated with variability in component preparation and supports compliance with global regulatory requirements. The processes are documented in Drug Master Files (DMF) with regulatory bodies such as the U.S. FDA and Health Canada.
The Westar® Select components build upon the foundation of the Westar® RS components by incorporating additional quality control measures. The Westar® Select component manufacturing is particularly beneficial for applications where higher levels of quality and risk mitigation is required as it is designed with tighter particle specification and visual inspection criteria. Both the Westar® and Westar® Select processes are integral to West's commitment to providing high-quality, reliable packaging solutions that meet the evolving needs of the pharmaceutical industry. By ensuring that components are prepared to the high standards, these processes help pharmaceutical companies maintain the integrity of their drug products and comply with regulatory requirements. It provides an additional layer of assurance that the components will not compromise the safety or efficacy of the drug product.
NovaPure® components are a premium line of pharmaceutical packaging solutions developed by West. These components are designed to offer the highest levels of quality, performance, and risk mitigation, making them ideal for use in modern drug containment and delivery systems, particularly for biologic drugs and self-administration devices such as prefilled syringes and auto-injectors. Developed using Quality by Design (QbD) principles, these components benefit from a systematic, science-based approach that enhances process understanding and product quality, with continuous improvements driven by statistical analysis. The application of FluroTec™ barrier film currently on all stoppers and plungers minimizes drug-elastomer interactions, reducing leachables and lowers risk to drug stability and efficacy. NovaPure® components adhere to the tightest particulate specifications, undergoing rigorous testing to meet critical process parameters, with ongoing enhancements through annual reviews. Available in bromobutyl and chlorobutyl formulations, NovaPure® components are versatile and compatible with various drug delivery systems, offering optimal risk mitigation and enhancing consistency.
In addition, the West Envision™ verification process is an advanced automated vision verification system by West, designed to enhance the quality of pharmaceutical packaging components by significantly reducing particulates and defects that would otherwise be found in the final product . Unlike traditional sampling methods, the Envision™ verification process ensures 100% component verification by inspecting every component, thereby guaranteeing comprehensive defect detection. Utilizing a program-controlled automated vision system, it examines all surfaces of elastomeric components to identify defects such as contamination and molding issues. Conducted in a controlled Zone 5 clean room, the inspections minimize contamination risks, effectively reducing the likelihood of drug product rejection and recalls by minimizing visible particulates and defects. Implemented globally, the Envision™ verification process is supported by a harmonized validation plan, ensuring consistent quality across all regions. Customers benefit from this process through reduced particle contamination, higher yields, less waste, and improved throughput, making it an invaluable tool in maintaining the safety and efficacy of pharmaceutical products.
The sterilization of packaging components is crucial to ensure that no microbial contaminants compromise the sterile drug product. Common sterilization methods include steam sterilization, gamma irradiation , ethylene oxide treatment, and electron beam. Each method's suitability depends on the packaging component material and its thermal or chemical sensitivity of the drug product . The chosen sterilization process must be validated to confirm its efficacy without altering the packaging material's properties or its capacity to maintain drug stability. West recommendation for elastomeric components is steam sterilization. Sterile, ready-to-use elastomeric components have been the focus of increasing requests from the pharmaceutical and biotechnology market segments. For West ready-to-use steam sterilized products, West’s validation approach utilizes a half cycle validation method in which Biological Indicators are used based on ISO 17665-1 and ISO 17665-2 Sterilization of Healthcare Products – Moist Heat. Biological indicators are used during the validation to demonstrate appropriate kill at established West validated cycle parameters . The steam sterilization process is validated to achieve a Sterility Assurance Level (SAL) of 10-6 or better. During the routine manufacturing sterility assurance is ensured through review of the autoclave cycle parameters. Steam-sterilized ready-to-use elastomeric components are provided in various packaging formats. Customers have the option to choose from ported or non-ported STERILIZABLEBAG™ packaging systems. Stoppers designed to be used in a lyophilization process are packaged in a secondary moisture barrier bag post sterilization to maintain the dryness of the stoppers.
West prepared a comprehensive range of Drug Master Files (DMFs), Master Access Files (MAFs), 510ks, and Canadian Licenses, registered with the U.S. FDA, China CDE (Center for Drug Evaluation, National Medical Products Administration) or Health Canada accordingly. Many of our DMFs are some of the most frequently accessed at these agencies. We provide Letters of Authorization/Access (LOAs) to customers for inclusion in their drug applications, which can be requested through our streamlined online request form. Annually, West issues over 1800 LOAs related to our DMFs.
Our Regulatory Affairs (RA) team has collaborated with the U.S. FDA and Health Canada to develop industry standards for converting packaging and process DMFs to electronic format (eCTD). West's entire DMF portfolio is now in eCTD format, ensuring compliance with both U.S. FDA and Health Canada’s electronic DMF requirements.
Additionally, we offer Global Submission Support Packages to aid customers in countries without established DMFs and MAFs systems. These packages provide the necessary technical information about West products and processes, tailored to meet Health Authority requirements for pharmaceutical components and delivery systems in drug applications. Each package is backed by support from West RA to address any inquiries from reviewing agencies.
The blog highlights critical considerations when optimizing primary packaging for injectable drugs, ensuring their safety, efficacy, and quality. Key points include adherence to regulatory requirements like USP <382> (effective from 01st Dec 2025), EU GMP Annex 1, and EU Medical Device Regulation (MDR) 2017/745, which provide frameworks for ensuring packaging components maintain drug integrity through functional suitability and contamination control. Compatibility between drug formulations and packaging materials is emphasized as vital for preventing adverse interactions that may degrade drug efficacy. The importance of protecting against extractables and leachables through testing and using FluroTec™ barrier film product is discussed, ensuring drug purity and compliance. The design of packaging components, especially through Quality by Design (QbD) principles, is outlined to ensure robustness, reliability, and high performance under stringent conditions. Furthermore, emphasis is placed on container closure integrity testing (CCI), preparation methods and specifications, and sterilization processes to maintain sterility and avoid contamination. Documentation and services like Drug Master Files (DMFs) and Letters of Authorization are highlighted for their role in supporting regulatory compliance and facilitating global submissions.
In conclusion, the careful selection and robust evaluation of primary packaging components for injectable drugs are fundamental to ensuring their safety, efficacy, and compliance with regulatory standards. By integrating testing, innovative design, and comprehensive compatibility studies, manufacturers can safeguard the integrity and performance of their products throughout their lifecycle. The comprehensive regulatory documentation and global support services offered by West further empower pharmaceutical companies to meet stringent industry requirements and seamlessly navigate complex regulatory landscapes.
As you consider the intricacies of pharmaceutical packaging components, we invite you to explore how West's innovative solutions and extensive documentation services can enhance your product's journey from development to market. Reach out to us for assistance tailored to your specific packaging needs and let us help you achieve the highest standards for your injectable drug products.
English
Chinese
